Unexplored limitations in a randomized trial that examines efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: comment on the article by Merrill et al

Ähnliche Einträge

• Endometriosis as a comorbidity in pregnant patients with systemic lupus erythematosus: comment on the article by Nguyen et al
  von: Maria I. Zervou, et al.
  Veröffentlicht: (2026)
• Hydroxychloroquine dose after hospitalization for systemic lupus erythematosus: comment on the article by Nestor et al
  von: Berçemhan Sulu, et al.
  Veröffentlicht: (2025)
• Drivers of subclinical vascular disease in systemic lupus erythematosus: comment on the article by Oliveira et al
  von: Biao Song, et al.
  Veröffentlicht: (2025)
• Systemic lupus erythematosus and atherosclerosis progression risk: comment on the article by Papazoglou et al.
  von: Yusuf Ziya Sener, et al.
  Veröffentlicht: (2025)
• The effect of air pollution and genetic susceptibility on systemic lupus erythematosus: comment on the article by Xing et al
  von: Na Wang, et al.
  Veröffentlicht: (2024)